Adalimumab: Long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

Gerd R. Burmester*, Remo Panaccione, Kenneth B. Gordon, Melissa J. McIlraith, Ana P.M. Lacerda

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

451 Scopus citations

Fingerprint

Dive into the research topics of 'Adalimumab: Long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

INIS